Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vector Science and Therapeutics ROE % Adjusted to Book Value Chart
Vector Science and Therapeutics Annual Data
Trend
Aug24
Aug25
ROE % Adjusted to Book Value
0.00
0.00
Vector Science and Therapeutics Quarterly Data
Aug24
Nov24
Aug25
Nov25
Feb26
ROE % Adjusted to Book Value
0.00
0.00
0.00
0.00
0.00
TSXV:PAIN vs ABT, SYK, MDT: ROE % Adjusted to Book Value Comparison
For the Medical Devices subindustry, Vector Science and Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vector Science and Therapeutics ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vector Science and Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Vector Science and Therapeutics's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 0.00% mean?
Vector Science and Therapeutics (TSXV:PAIN) has a ROE % Adjusted to Book Value of 0.00% as of Feb. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vector Science and Therapeutics and its competitors.
Is Vector Science and Therapeutics' ROE % Adjusted to Book Value too high?
Vector Science and Therapeutics' current ROE % Adjusted to Book Value is 0.00%. Overall, Vector Science and Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Vector Science and Therapeutics' ROE % Adjusted to Book Value compare to ABT and SYK?
Vector Science and Therapeutics' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vector Science and Therapeutics and its competitors. Vector Science and Therapeutics's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vector Science and Therapeutics stock overvalued right now?
Vector Science and Therapeutics (TSXV:PAIN) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Vector Science and Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Vector Science and Therapeutics (TSXV:PAIN), the current ROE % Adjusted to Book Value is 0.00% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vector Science and Therapeutics Business Description
Vector Science and Therapeutics Corp develops novel biomechanical devices and active transdermal drug and peptide delivery platforms to equip clinicians with non-systemic, localized interventions targeting a broad cross-section of diseases and conditions where systemic delivery of interventions compromises the therapeutic effect or introduces unacceptable harm.
14GF Score
Get the complete analysis for TSXV:PAIN
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:PAIN has been successfully added to your 
